Researchers examined data on more than 600,000 people, comparing patients who were prescribed aspirin over a long period (average duration was 7.7 years) and patients who were not aspirin users.
They found that long-term aspirin users showed a:
● 47 percent reduction in liver and oesophageal cancer incidence
● 38 percent reduction in gastric cancer incidence
● 34 percent reduction in pancreatic cancer incidence
● 24 percent reduction in colorectal cancer incidence
“What should be noted is the significance of the results for cancers within the digestive tract, where the reductions in cancer incidence were all very substantial, especially for liver and oesophageal cancer,” said Professor Kelvin Tsoi, lead researcher from the Chinese University of Hong Kong.
More articles on healthcare quality:
CDC reports 1st pediatric flu death for 2017-2018 flu season
Flu vaccine improves outcome rate for other infections: 6 study findings
Top 10 infection control stories, Oct. 23-27
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
